DE60105807D1 - Verfahren zur Herstellung einer stabilen pharmazeutischen Zusammensetzung enthaltend mikronisiertes Formoterol - Google Patents

Verfahren zur Herstellung einer stabilen pharmazeutischen Zusammensetzung enthaltend mikronisiertes Formoterol

Info

Publication number
DE60105807D1
DE60105807D1 DE60105807T DE60105807T DE60105807D1 DE 60105807 D1 DE60105807 D1 DE 60105807D1 DE 60105807 T DE60105807 T DE 60105807T DE 60105807 T DE60105807 T DE 60105807T DE 60105807 D1 DE60105807 D1 DE 60105807D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
preparation
stable pharmaceutical
composition containing
containing micronized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60105807T
Other languages
English (en)
Other versions
DE60105807T2 (de
Inventor
Eva Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60105807(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60105807D1 publication Critical patent/DE60105807D1/de
Application granted granted Critical
Publication of DE60105807T2 publication Critical patent/DE60105807T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Catalysts (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Saccharide Compounds (AREA)
DE60105807T 2000-05-19 2001-05-17 Verfahren zur Herstellung einer stabilen pharmazeutischen Zusammensetzung enthaltend mikronisiertes Formoterol Expired - Lifetime DE60105807T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012261.4A GB0012261D0 (en) 2000-05-19 2000-05-19 Novel process
GB0012261 2000-05-19
PCT/SE2001/001117 WO2001089491A1 (en) 2000-05-19 2001-05-17 Novel process

Publications (2)

Publication Number Publication Date
DE60105807D1 true DE60105807D1 (de) 2004-10-28
DE60105807T2 DE60105807T2 (de) 2005-11-24

Family

ID=9892016

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105807T Expired - Lifetime DE60105807T2 (de) 2000-05-19 2001-05-17 Verfahren zur Herstellung einer stabilen pharmazeutischen Zusammensetzung enthaltend mikronisiertes Formoterol

Country Status (19)

Country Link
US (3) US7179489B2 (de)
EP (1) EP1289505B1 (de)
JP (3) JP5739597B2 (de)
KR (1) KR100799452B1 (de)
CN (1) CN1245962C (de)
AT (1) ATE276748T1 (de)
AU (2) AU2001259006B2 (de)
BR (1) BRPI0110947B8 (de)
CA (1) CA2409660C (de)
DE (1) DE60105807T2 (de)
ES (1) ES2227190T3 (de)
GB (1) GB0012261D0 (de)
IL (2) IL152532A0 (de)
MX (1) MXPA02011310A (de)
NO (1) NO20025220D0 (de)
NZ (1) NZ522419A (de)
PT (1) PT1289505E (de)
WO (1) WO2001089491A1 (de)
ZA (1) ZA200208710B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
EP1599209B1 (de) 2002-08-21 2011-08-17 Norton Healthcare Limited Inhalationszusammensetzung
US20040105821A1 (en) * 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
AU2004262902B2 (en) * 2003-07-29 2009-07-30 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
EP1670482B2 (de) 2003-09-16 2022-06-29 Covis Pharma B.V. Verwendung von ciclesonid zur behandlung von atemwegserkrankungen
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20080293788A1 (en) * 2004-06-14 2008-11-27 Sullivan Anne M Methods and Compositions for the Treatment of Pulmonary Diseases
RU2007133547A (ru) 2005-02-10 2009-03-20 Глаксо Груп Лимитед (GB) Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
WO2010144043A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab A novel 4-methylbenzenesulphonate salt and a process for preparing a pharmaceutical composition comprising the salt
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011104360A1 (en) * 2010-02-25 2011-09-01 Andi-Ventis Limited Formulation of compositions for the treatment of inflammatory conditions
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
EP2804583A1 (de) * 2012-01-16 2014-11-26 Mahmut Bilgic Trockenpulverformulierungen mit r-formoterol als wirkstoff
NZ722952A (en) * 2012-02-28 2018-12-21 Iceutica Holdings Inc Inhalable pharmaceutical compositions
EP4034079A1 (de) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Neuartige trägerpartikel für trockenpulverformulierungen zur inhalation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
ES2079743T3 (es) * 1991-07-01 1996-01-16 Gergely Gerhard Tableta para chupar o masticar.
JPH0558911A (ja) * 1991-08-27 1993-03-09 N D Shinyaku Kaihatsu Kenkyusho:Kk 鎮咳去痰剤
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US6034604A (en) * 1999-01-14 2000-03-07 Kaltner; George Deactivation prevention for electronic article surveillance systems
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
CN1245962C (zh) 2006-03-22
BR0110947A (pt) 2003-04-29
JP2015042693A (ja) 2015-03-05
US7179489B2 (en) 2007-02-20
EP1289505A1 (de) 2003-03-12
NO20025220L (no) 2002-10-31
BRPI0110947B1 (pt) 2016-12-27
CA2409660A1 (en) 2001-11-29
JP2013040214A (ja) 2013-02-28
US20070259048A1 (en) 2007-11-08
WO2001089491A1 (en) 2001-11-29
ZA200208710B (en) 2004-02-10
CN1429103A (zh) 2003-07-09
JP5739597B2 (ja) 2015-06-24
JP2003534272A (ja) 2003-11-18
BRPI0110947B8 (pt) 2021-05-25
US7670625B2 (en) 2010-03-02
US20030129245A1 (en) 2003-07-10
KR100799452B1 (ko) 2008-01-30
IL219785A0 (en) 2012-06-28
CA2409660C (en) 2011-02-08
AU5900601A (en) 2001-12-03
NZ522419A (en) 2003-08-29
AU2001259006B2 (en) 2005-03-24
ES2227190T3 (es) 2005-04-01
IL219785A (en) 2015-10-29
MXPA02011310A (es) 2003-04-25
KR20030001514A (ko) 2003-01-06
EP1289505B1 (de) 2004-09-22
DE60105807T2 (de) 2005-11-24
US20100183729A1 (en) 2010-07-22
PT1289505E (pt) 2005-01-31
GB0012261D0 (en) 2000-07-12
ATE276748T1 (de) 2004-10-15
NO20025220D0 (no) 2002-10-31
IL152532A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
DE60105807D1 (de) Verfahren zur Herstellung einer stabilen pharmazeutischen Zusammensetzung enthaltend mikronisiertes Formoterol
DE60105147D1 (de) Verfahren zur Herstellung einer stabilen mikronisierten Zusammensetzung von Formoterol mit einem Glucocorticosteroid
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
SE9900833D0 (sv) Novel combination
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
MXPA04007294A (es) Composicion para inhalacion.
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2002095008A3 (en) Methods of modulating surfactant phospholipid production

Legal Events

Date Code Title Description
8363 Opposition against the patent